Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040521 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating rhIL-11 in Active Crohn's Disease
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00040521: Completed Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00040521 is a Phase 2 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00040521, a Phase 2 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to assess the activity of multiple doses of oral rhIL-11 in patients with active Crohn's disease (Crohn's Disease Activity Index \[CDAI\] score from 220-400).
Interventions
- DRUG Recombinant Human Interleukin-11 (rhIL-11)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04 |
| Est. Completion | 2003-10 |
| Phase | Phase 2 |
What the finished NCT00040521 record still lists
NCT00040521 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Recombinant Human Interleukin-11 (rhIL-11) is the first listed.
NCT00040521 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00040521 about?
NCT00040521 is a clinical study titled "Study Evaluating rhIL-11 in Active Crohn's Disease". The purpose of this study is to assess the activity of multiple doses of oral rhIL-11 in patients with active Crohn's disease (Crohn's Disease Activity Index \[CDAI\] score from 220-400).
What is the current status of trial NCT00040521?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-04. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00040521?
The interventions under investigation include: Recombinant Human Interleukin-11 (rhIL-11) (DRUG).
Who is sponsoring clinical trial NCT00040521?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia